The detection of CTCs via a blood sample that includes confirmatory markers of tissue origin (EGFR in lung cancer or HER2 in breast cancer and GI malignancies, for instance) may establish a sound medical rationale for confirmation of a cancer diagnosis and subsequent treatment. Here, ERBB2 is linked to breast cancer.